Cardiac energetics & heart failure support

What actually decides this outcome, in order of size

Every positive trial on this page was run in a diagnosed, treated heart. That single fact reorders the list. Ranked by how much of the outcome each one owns:

1. Whether there is a cardiomyopathy at all, because the evidence here does not exist outside one. The coenzyme Q10 morbidity and mortality result was obtained in patients with chronic heart failure Mortensen 2014, which means it was given on top of whatever those patients were already being treated with. It is an ADD-ON result. An add-on result cannot be moved into somebody with a structurally normal heart and no background treatment, because the thing it was added to is missing.
2. Guideline pharmacotherapy, which is not on this page and outranks all of it. Neurohormonal blockade has mortality data that no supplement in this list approaches. Anything here is an adjunct by design, and a reader who reads it as an alternative has inverted the order in the direction that costs the most.
3. Ejection fraction phenotype, because it changes which trial applies. Ubiquinol with or without D-ribose was studied specifically in heart failure with preserved ejection fraction Pierce 2022, which is a different disease from the reduced-fraction population the coenzyme Q10 mortality work used. The two are routinely quoted together on supplement pages as though they were one literature.
4. Whether the substrate is actually low, which is measurable and almost never measured. Plasma coenzyme Q10 can be quantified by validated chromatographic methods Paredes-Fuentes 2022 and carnitine can be measured as total and free. Supplementing a substrate without knowing the concentration is the definition of an untargeted intervention.
5. The compounds, last, and the second-best evidenced is a hawthorn extract with an explicit benefit-risk review Holubarsch 2018. Taurine's human heart failure literature has been systematically reviewed and is thin McGurk 2022. Neither belongs above the first two items.

The order to run these in, and what has to be true first

Establish the diagnosis, get the guideline therapy right with a cardiologist, and only then decide whether an energetic adjunct has a place. Reversing that order is the failure mode this page is most likely to cause.

1. The diagnosis is imaging and a cardiologist, not a marker. An echocardiogram gives the ejection fraction that decides which of the trials above even applies Pierce 2022. No blood test on this site substitutes for it, and this is the step that changes what happens next.
2. One panel to describe the terrain. Comprehensive Metabolic Panel (CMP) for electrolytes and renal function, because potassium and creatinine constrain every cardiac drug. hs-CRP (High-Sensitivity C-Reactive Protein) and the Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) with ApoB (Apolipoprotein B) for the atherosclerotic side, and Lipoprotein(a) — Lp(a) once in a lifetime because it is genetically set. HbA1c (Hemoglobin A1c), because diabetes changes the phenotype.
3. Measure the substrate before buying it. Coenzyme Q10 and Carnitine, Total and Free are both orderable, and both are the rare case where the supplement has a matching assay Paredes-Fuentes 2022. A normal level is a reason not to spend, and it is the commonest result.
4. CoQ10 or Ubiquinol first if anything is taken, with the formulation question stated. Ubiquinone and ubiquinol have been compared as cardiovascular supplements Fladerer 2023, and the absorption of coenzyme Q10 is limited and formulation-dependent rather than dose-dependent, which is why a large labeled milligram figure is not automatically a larger exposure.
5. D-Ribose only alongside the preserved-fraction trial that studied it Pierce 2022, and with the awareness that it is a reducing sugar. It lowers blood glucose acutely, which matters to anybody on insulin or a sulfonylurea and to anybody using HbA1c (Hemoglobin A1c) to follow something else.
6. L-Carnitine L-Tartrate and Taurine next, and low. Oral carnitine's effect on exercise variables has been reviewed Mielgo-Ayuso 2021, muscle carnitine is difficult to raise from plasma, and the taurine review found the human cardiac evidence limited McGurk 2022.
7. Hawthorn with the benefit-risk review attached rather than the folklore Holubarsch 2018. Magnesium and Potassium are electrolytes with real arrhythmic relevance and real danger in renal impairment, which is why they follow the Comprehensive Metabolic Panel (CMP) rather than precede it.
8. SS-31, Nad+, Mirabegron, Cardiogen and Chelohart are the experimental tail. Mitochondria-targeted and receptor-directed cardiac agents are an active preclinical field, including nuclear-receptor agonists that improve cardiac energetics in models Xu 2023; the peptide bioregulators' cardiac work is animal and Soviet-era Levdik 2009, and the argument for that series sits at Vascular, cardiac & structural.

What gets bought for this that cannot move it

The category that fails structurally is the energetic supplement bought by somebody with a normal heart. These molecules are substrate and cofactor for oxidative phosphorylation, and a heart that is not energy-limited has no deficit for them to fill. That is why the trials were run in failing hearts, and it is why quoting a heart failure mortality result Mortensen 2014 to a well 45-year-old is not optimism, it is a category error. The honest prediction in a normal heart is nothing measurable.

D-ribose is the option on this page whose marketing most exceeds its result. The premise is that replenishing the pentose backbone accelerates adenine nucleotide resynthesis in an energy-starved myocardium. The randomized test of that idea, in the phenotype it was designed for, is a single modest study Pierce 2022, and the supplement is sold on the mechanism rather than on the trial.

An adjunct cannot be a substitute, and this is the sentence that matters most on the page. Nothing here is a reason to reduce, delay or stop a prescribed cardiac medication, and a supplement that improved symptoms would still be improving them on top of the drug that was keeping the person alive. The benefit-risk framing used for hawthorn Holubarsch 2018 is the right frame for the whole page.

If the complaint is different, so is the page. Breathlessness on exertion in somebody with no diagnosis is a clinician, not a shelf. Cholesterol and particle number is ApoB & LDL particle reduction. Blood pressure and vessel tone is Endothelial function & nitric oxide. Clotting risk and lipoprotein(a) is Thrombosis, Lp(a) & residual risk. Chest pain at rest, new breathlessness lying flat, or ankles that pit is an emergency assessment today.

How you would know it was working, on a real read-out and a real timescale

This page makes a prediction that most readers will find disappointing and should. In a normal heart, nothing here changes a measurable variable, and the correct read-out is the panel that says so. In a diagnosed cardiomyopathy the read-out is functional capacity and symptom class assessed by the treating team, with the markers below answering only whether the substrate story was ever true.

• Coenzyme Q10 at baseline and at 8 to 12 weeks if supplementing. This is the rare supplement with a validated plasma assay Paredes-Fuentes 2022, so the first question, whether the capsule is being absorbed at all, is answerable. Eight weeks because plasma coenzyme Q10 reaches a new steady state over weeks rather than days.
• Carnitine, Total and Free once, total and free. A normal plasma carnitine with a normal renal function is a reason not to buy the carnitine, and plasma poorly reflects the muscle pool in any case Mielgo-Ayuso 2021.
• Comprehensive Metabolic Panel (CMP) before and after any electrolyte, without exception. Potassium supplementation with impaired renal clearance is the single most dangerous thing a reader could do from this page, and creatinine on the same panel is what tells you whether that applies.
• High-Sensitivity Troponin T is a diagnostic test and not a monitoring test. It answers whether myocardium is being injured right now, which is an emergency question. Ordering it serially to follow a supplement produces false alarms and does not answer anything this page can act on.
• A fixed functional test, weekly. Distance covered on a flat route at a fixed effort, or stairs climbed before stopping. Symptom class is the endpoint the heart failure trials moved Mortensen 2014, and a home version of it is more informative than any of the markers above.

What will fool you. Heart failure symptoms fluctuate with sodium intake, with fluid status and with the last diuretic dose, so a good fortnight is common and means little. Coenzyme Q10 falls with statin therapy, so a low value in somebody who has just started a statin is expected rather than causal Fladerer 2023. D-ribose lowers glucose and will move an HbA1c (Hemoglobin A1c) that was being used to watch something else Pierce 2022. And guideline therapy is usually being titrated at the same time as the supplement is started, which gives the supplement the credit for the drug.

Sources read for these sections

• Mortensen SA, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure, 2014 · PMID 25282031
• Fladerer JP, et al. Comparison of Coenzyme Q10 (Ubiquinone) and Reduced Coenzyme Q10 (Ubiquinol) as Supplement to Prevent Cardiovascular Disease and Reduce Cardiovascular Mortality. Current Cardiology Reports 2023 · PMID 37971634
• Pierce JD. Effects of Ubiquinol and/or D-ribose in Patients With Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology 2022 · PMID 35644694
• McGurk KA. Effect of taurine administration on symptoms, severity, or clinical outcome of dilated cardiomyopathy and heart failure in humans: a systematic review. Wellcome Open Research 2022 · PMID 35855073
• Holubarsch CJF. Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review. American Journal of Cardiovascular Drugs 2018 · PMID 29080984
• Mielgo-Ayuso J. Effect of Acute and Chronic Oral l-Carnitine Supplementation on Exercise Performance Based on the Exercise Intensity: A Systematic Review. Nutrients 2021;13(12):4359 · PMID 34959912
• Paredes-Fuentes AJ, et al. Technical Aspects of Coenzyme Q10 Analysis: Validation of a New HPLC-ED Method. Antioxidants 2022 · PMID 35326178
• Xu W, Billon C, Li H, Wilderman A, Qi L, Graves A, Rideb JRDC, Zhao Y, Hayes M, Yu K, Losby M, Hampton CS, Adeyemi CM, Hong SJ, Nasiotis E, Fu C, Oh TG, Fan W, Downes M, Welch RD, Evans RM, Milosavljevic A, Walker JK, Jensen BC, Pei L, Burris T, Zhang L. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.. Circulation 2023 · PMID 37961903
• Levdik NV, et al. Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. Bulletin of Experimental Biology and Medicine 2009 · PMID 20396706